COX-2 inhibitors--a lesson in unexpected problems.

Drazen JM

doi:10.1056/nejme058038

COX-2 inhibitors--a lesson in unexpected problems.

Drazen JM

ORCIDs linked to this article

Drazen JM | 0000-0003-2715-9890

The New England Journal of Medicine, 15 Feb 2005, 352(11):1131-1132
https://doi.org/10.1056/nejme058038 PMID: 15713947

A comment on this article appears in "Cardiovascular risk associated with celecoxib." N Engl J Med. 2005 Jun 23;352(25):2648-50; author reply 2648-50. This is a comment on "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial." N Engl J Med. 2005 Mar 17;352(11):1092-102. This is a comment on "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention." N Engl J Med. 2005 Mar 17;352(11):1071-80. Show all (4)

Abstract

No abstract provided.

Full text links

Read article at publisher's site: https://doi.org/10.1056/nejme058038

References

Articles referenced by this article (11)

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators
N Engl J Med, (11):1071-1080 2005
MED: 15713944
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM
N Engl J Med, (11):1081-1091 2005
MED: 15713945
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
N Engl J Med, (11):1092-1102 2005
MED: 15713943
Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes.
Tanaka Y, Ward SL, Smith WL
J Biol Chem, (3):1374-1381 1987
MED: 3100531
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS
JAMA, (10):1247-1255 2000
MED: 10979111
Risk of cardiovascular events associated with selective COX-2 inhibitors.
Mukherjee D, Nissen SE, Topol EJ
JAMA, (8):954-959 2001
MED: 11509060
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group
N Engl J Med, (21):1520-8, 2 p following 1528 2000
MED: 11087881
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA
Proc Natl Acad Sci U S A, (1):272-277 1999
MED: 9874808
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM
N Engl J Med, (11):1081-1091 2005
MED: 15713945
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators
N Engl J Med, (11):1071-1080 2005
MED: 15713944

Show 1 more reference (10 of 11)

Citations & impact

Impact metrics

Citations

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/113108531

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/113108531

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1056/nejme058038

Supporting

Mentioning

Contrasting

Article citations

New Thiazole Carboxamide Derivatives as COX Inhibitors: Design, Synthesis, Anticancer Screening, In Silico Molecular Docking, and ADME Profile Studies.
Hawash M, Jaradat N, Sabobeh R, Abualhasan M, Qaoud MT
ACS Omega, 8(32):29512-29526, 06 Aug 2023
Cited by: 3 articles | PMID: 37599929 | PMCID: PMC10433355
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.
Cronin SJF, Rao S, Tejada MA, Turnes BL, Licht-Mayer S, Omura T, Brenneis C, Jacobs E, Barrett L, Latremoliere A, Andrews N, Channon KM, Latini A, Arvanites AC, Davidow LS, Costigan M, Rubin LL, Penninger JM, Woolf CJ
Sci Transl Med, 14(660):eabj1531, 31 Aug 2022
Cited by: 11 articles | PMID: 36044597 | PMCID: PMC9985140
Free full text in Europe PMC
Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer's disease.
Tyler SEB, Tyler LDK
Nat Prod Bioprospect, 12(1):34, 23 Aug 2022
Cited by: 2 articles | PMID: 35996065 | PMCID: PMC9395556
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
Higurashi T, Arimoto J, Ashikari K, Takatsu T, Misawa N, Yoshihara T, Matsuura T, Fuyuki A, Ohkubo H, Nakajima A
BMC Cancer, 20(1):770, 17 Aug 2020
Cited by: 1 article | PMID: 32807113 | PMCID: PMC7433177
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Curcumin in Autoimmune and Rheumatic Diseases.
Yang M, Akbar U, Mohan C
Nutrients, 11(5):E1004, 02 May 2019
Cited by: 31 articles | PMID: 31052496 | PMCID: PMC6566522
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Go to all (95) article citations

Search life-sciences literature (45,103,589 articles, preprints and more)

COX-2 inhibitors--a lesson in unexpected problems.

ORCIDs linked to this article

Abstract

Full text links

References

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Risk of cardiovascular events associated with selective COX-2 inhibitors.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1056/nejme058038

Article citations

New Thiazole Carboxamide Derivatives as COX Inhibitors: Design, Synthesis, Anticancer Screening, In Silico Molecular Docking, and ADME Profile Studies.

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.

Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer's disease.

The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.

Curcumin in Autoimmune and Rheumatic Diseases.

Similar Articles

COX-2 inhibitors--lessons in drug safety.

Coxibs and cardiovascular disease.

Raising the safety bar--the FDA's coxib meeting.

The coxibs, selective inhibitors of cyclooxygenase-2.

Partnerships & funding

Similar Articles

COX-2 inhibitors--lessons in drug safety.
N Engl J Med, 352(11):1133-1135, 15 Feb 2005

Coxibs and cardiovascular disease.
N Engl J Med, 351(17):1709-1711, 06 Oct 2004

Raising the safety bar--the FDA's coxib meeting.
N Engl J Med, 352(13):1283-1285, 01 Mar 2005

The coxibs, selective inhibitors of cyclooxygenase-2.
N Engl J Med, 345(6):433-442, 01 Aug 2001

Search life-sciences literature (45,103,589 articles, preprints and more)

COX-2 inhibitors--a lesson in unexpected problems.

Author information

ORCIDs linked to this article

Abstract

Full text links

References

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Similar Articles

Partnerships & funding